Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (121-130 of 222) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2022
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate CancerEric Feng, Nicholas R Rydzewski, Meng Zhang, et al.
Metabolites|March 3, 2021
Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor ModelsJinny Sun, Robert A Bok, Justin DeLos Santos, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
American Journal of Preventive Cardiology|April 20, 2026
Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-ITRahul Aggarwal, Deepak L Bhatt, Michael Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor MalignanciesRahul Aggarwal, Scott Thomas, Nela Pawlowska, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Pageof 23

Showing results (121-130 of 222) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2022
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate CancerEric Feng, Nicholas R Rydzewski, Meng Zhang, et al.
Metabolites|March 3, 2021
Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor ModelsJinny Sun, Robert A Bok, Justin DeLos Santos, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
American Journal of Preventive Cardiology|April 20, 2026
Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-ITRahul Aggarwal, Deepak L Bhatt, Michael Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor MalignanciesRahul Aggarwal, Scott Thomas, Nela Pawlowska, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Pageof 23